Cargando…
Hypertension as a predictive biomarker in patients with advanced non-small-cell lung cancer treated with apatinib
BACKGROUND: Hypertension (HTN) is a common adverse event of the vascular endothelial growth factor pathway inhibitor apatinib. This study was conducted to evaluate the association of apatinib-induced HTN with clinical outcomes in patients with advanced non-small-cell lung cancer (NSCLC). METHODS: We...
Autores principales: | Fang, Shen-Cun, Huang, Wen, Zhang, Ying-Ming, Zhang, Hai-Tao, Xie, Wei-Ping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6362948/ https://www.ncbi.nlm.nih.gov/pubmed/30774384 http://dx.doi.org/10.2147/OTT.S189984 |
Ejemplares similares
-
Apatinib as post second-line therapy in EGFR wild-type and ALK-negative advanced lung adenocarcinoma
por: Fang, Shen-Cun, et al.
Publicado: (2017) -
Salvage treatment with apatinib for advanced non-small-cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2017) -
Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review
por: Yang, Dexiang, et al.
Publicado: (2018) -
Fatal hemoptysis in patients with advanced esophageal cancer treated with apatinib
por: Wang, Wei, et al.
Publicado: (2018) -
Low-dose apatinib monotherapy in advanced chemotherapy-refractory
small cell lung cancer: a case series and literature review
por: Liu, Ying-ying, et al.
Publicado: (2019)